-transparent.png){kind=logo}
Treatment of rats with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) resulted in a pronounced loss of alpha 2-adrenoceptor binding ( [3H]RX-781094) and a marked reduction in the ability of the alpha 2-agonist UK-14,304 to inhibit K+-stimulated release of both [3H]NA and [3H]5-HT in cerebral cortex. Repopulation of alpha 2-adrenoceptors was monoexponential with a t1/2 of 4.1 days; functional recovery was also monoexponential, with t1/2 values of 2.4 and 4.6 days for restoration of alpha 2-mediated inhibition of [3H]NA and [3H]5-HT release, respectively. Other studies suggest the difference in functional recovery rate may reflect the presence of a large receptor reserve for autoreceptors relative to heteroreceptors.
C H Adler, and
E Meller, and
M Goldstein
March 1997,
Proceedings of the National Academy of Sciences of the United States of America,
C H Adler, and
E Meller, and
M Goldstein
January 1991,
Proceedings of the Western Pharmacology Society,
C H Adler, and
E Meller, and
M Goldstein
July 1996,
Brain research,
C H Adler, and
E Meller, and
M Goldstein
July 1990,
Biochemical pharmacology,
C H Adler, and
E Meller, and
M Goldstein
September 1994,
Biochemical pharmacology,
C H Adler, and
E Meller, and
M Goldstein
October 1997,
Brain research. Brain research protocols,
C H Adler, and
E Meller, and
M Goldstein
January 1988,
Advances in experimental medicine and biology,
C H Adler, and
E Meller, and
M Goldstein
September 1970,
Life sciences. Pt. 1: Physiology and pharmacology,
C H Adler, and
E Meller, and
M Goldstein
May 1972,
European journal of pharmacology,
C H Adler, and
E Meller, and
M Goldstein
January 1989,
Life sciences,
